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Summary One hundred and sixty one children who have developed more than one primary neoplasm have
been identified. Children with tumours of the central nervous system, retinoblastoma and leukaemia were
those most frequently observed to develop a second malignancy whilst osteosarcoma was the most common
second tumour. The patterns of second neoplasms appear to be changing and a recent increase in the number
of children with leukaemia and lymphoma who develop second primary tumours has been observed. In this
series, the two most frequent associations of tumours were retinoblastoma followed by osteosarcoma and the
combination of acute leukaemia with a tumour of the central nervous system. Genetic factors which may
have contributed to the development of the second primary tumour were identified in 53 patients (33%), 33 of
whom had the genetic form of retinoblastoma. In an analysis of the treatment of 151 patients, for whom the
interval between the two neoplasms was greater than 12 months, the second malignancy was considered to be
'radiation associated' in 93 (61%). Fifty children (33%) had been treated with either single or multiple agent
chemotherapy which included an alkylating agent in 38. Forty five children had received a combination of
chemotherapy and radiotherapy and of these, 10 developed leukaemia as their second tumour. Of the 19
secondary leukaemias, 16 have occurred in patients treated since 1970.
About one in 10,000 children in Britain develop cancer each
year (Draper et al., 1982). At present about 50% of these
children can be expected to survive for at least five years
which means that there are -600 patients each year who
will become 'long term' survivors. A large proportion of
these survivors will reach adulthood, potentially 'cured' of
their tumours. Recently however, the considerable optimism
engendered amongst clinicians by this improvement in
survival has been tempered by a growing awareness that
patients who have been successfully treated for one cancer
appear to be at greater risk than the general population of
developing a second histologically distinct malignancy (Li,
1977; Mike et al., 1982; Meadows et al., 1985; Hawkins
et al., 1987). Although the occurrence of multiple primary
tumours in any individual may reflect an inherent predis-
position to cancer, it is likely that the therapies given to
eradicate the first tumour are significant factors in the
pathogenesis of many, perhaps most, second primary
tumours.
In an attempt to discern possible aetiological factors in the
development of multiple primary tumours in childhood
cancer patients, a registry has been established to identify
those patients treated in Britain who develop second
malignancies. The patterns of multiple tumours in these
patients are the subject of this study. In this report we
describe 161 patients who have developed more than one
primary neoplasm and examine the various factors which
may have influenced the development of the second primary
tumour. We have not attempted to estimate the risk of
developing a second tumour in this paper as an analysis of
incidence rates is the subject of a separate communication
(Hawkins et al., 1987). Our main purpose here is to
describe the patterns of multiple tumours that have been
observed and to identify the possible influence of genetic
factors and previous therapy in the pathogenesis of the
second tumour. Thirteen of the patients included in this
series have been described in previous case reports
(Anderson & Treip 1983; Judge et al., 1984; Koriech &
McNaught, 1981; Lee et al., 1975; Pearson et al., 1983;
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Prentice et al., 1980; Secker-Walker et al., 1985; Stevenson et
al., 1981; Ingram et al., 1987); a further 24 patients treated
in the Manchester region, have been included in a report of
second cancers in children from the Late Effects Study
Group (LESG) (Meadows et al., 1985) and 34 of the 37
patients with retinoblastoma were included in a paper on
second tumours in retinoblastoma by Draper et al. (1986).
Materials and methods
The criteria for inclusion of a patient in our registry of
multiple primary tumour cases were based on the principles
of Warren and Gates (1932) as follows: each tumour
presented its own distinct histological malignant pattern and
the possibility that either tumour was a metastasis was
excluded. All patients included in this report had their first
cancer diagnosed during the period 1940-1982 and were
below the age of 15 years at diagnosis of their first tumour.
Patients in whom the second tumour was diagnosed within
one year of the first tumour have been defined as
'simultaneous' double tumour cases and have been excluded
from the analysis of treatment factors, the rationale for this
being that chemotherapy and radiation are unlikely to be
significant factors in the pathogenesis of a second tumour
occurring within 12 months of treatment of the first. The
'simultaneous' cases have, however, been included in the
analysis of genetic factors. Although we know of 12 patients
with retinoblastoma who developed ectopic intracranial
lesions in the pineal or suprasellar region (Kingston et al.,
1985), in contrast to some series e.g. Abramson et al. (1984),
we have not included them as second tumour cases as in our
opinion the intracranial lesion in these cases is not histo-
logically distinct from the primary retinoblastoma.
Ascertainment of cases
Since 1962 the Childhood Cancer Research Group (CCRG)
in Oxford has been notified of the majority of tumours
occurring in children under the age of 15 years through the
national cancer registration schemes for England, Wales and
Scotland. In addition, three year survivors of childhood
cancer diagnosed between 1940 and 1961 have been
ascertained through certain cancer registries and hospitals
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for specific years of diagnosis. Subsequent tumours occurring
amongst these children have been identified through
abstraction of hospital records, follow up enquiries to
hospital consultants and general practitioners, death
certificates and further cancer registrations. More recently, a
system of 'flagging' three year survivors of childhood cancer
at the National Health Service Registers has been
undertaken, ensuring automatic notification of cancers
registered since 1971 and of deaths occurring at any time.
Further details of the ascertainment of cases will be given by
Hawkins et al. (1987).
Confirmation ofdiagnosis
Following the initial ascertainment of a possible multiple
primary tumour case, the diagnosis of both the first and
second tumour was, wherever possible, confirmed by review
of the relevant pathological material. For a few children with
retinoblastoma and tumours of the central nervous system,
no histological material was available and confirmation of
the diagnosis was based on review of the radiological and
clinical evidence. Following initial confirmation of a double
tumour case, details of the date and age of the patient at
diagnosis of each tumour, the sites of both tumours and the
treatment given for the first tumour were abstracted from
hospital and general practitioner's records. Additional
information, including the relationship of the second tumour
to the radiation field in individuals treated with radiation,
the presence of coexistent chronic disease or congenital
abnormalities in the patient and details of malignancies in
other members of the family, was also collected. Wherever
possible this information was supplemented by the personal
knowledge of clinicians involved in the care of the patient.
Results
Ten children developed a second tumour within one year of
diagnosis of their first tumour and details of these
'simultaneous' double tumour cases are outlined in Table I.
The distribution of the all 161 cases by type and year of
diagnosis of the first tumour is shown in Table II. All the
children with leukaemia (16 cases) and with non Hodgkin
lymphoma (7 cases) who have subsequently developed a
second tumour were diagnosed since 1970. The diagnoses of
the first and second tumour and the number of cases in each
diagnostic group are shown in Table III. Children with
tumours of the central nervous system (CNS) comprised the
Table I Simultaneous multiple primary tumour cases
Interval Genetic
First tumour Second tumour (months) disease
Astrocytoma Optic nerve 2 VRD
glioma
Astrocytoma Optic nerve 7 VRD
glioma
Astrocytoma Ca colon 6 Turcot's
Medulloblastoma Rhabdoid tumour 1 *
of kidney
Medulloblastoma Basal cell 6 Gorlin's
carcinoma syndrome
Ependymoma Leiomyosarcoma 2 Tuberose
of kidney sclerosis
Rhabdomysarcoma Hepatoblastoma I Klippel
of bladder Trenaunay
Weber syndrome
Neurofibrosarcoma Malignant 5 VRD
melanoma
Hodgkin's disease Non Hodgkin 10 None known
lymphoma
AML Neuroblastoma 2 None known
VRD=Von Recklinghausen's disease; *Association of embryonal
tumours of kidney and brain described by Bonnin et al. (1984).
largest group to develop a second primary tumour (45
patients). The second largest diagnostic group were children
with retinoblastoma (37 cases) of whom 30 had bilateral and
seven unilateral disease. Children with acute leukaemia and
lymphoma (33) formed the third largest group; for children
treated for their first cancer during the decade 1970-1979
they comprise nearly 50% of the total number of cases
developing a second cancer to date. Osteosarcoma was the
most frequently observed second tumour (35 cases),
accounting for nearly one in four of all the cases. Other
commonly observed second tumours were tumours of the
CNS (31 cases), carcinomas (24 cases), skin cancers (19
cases), acute leukaemia (19 cases) and soft tissue sarcoma
(18). Sixteen of the 19 cases of acute leukaemia occurring as
a second tumour have developed in children diagnosed and
treated since 1970. Details of four children who developed
more than two malignant neoplasms are shown in Table IV.
They are also included in Tables II and III but with their
first and second tumours only.
Table II Number of double tumour cases by year of diagnosis of 1st tumour including
'simultaneous' cases
Year ofdiagnosis offirst tumour
All
Diagnosis of Ist tumour 1940-49 1950-59 1960-69 1970-79 1980-82 years
CNS tumour 6 15 10 9 5 45
Retinoblastoma Il 8 14 4 - 37
Acute leukaemia - - - 14 2 16
Wilms' tumour 1 5 4 3 - 13
Hodgkin's disease - 1 3 6 - 10
Non Hodgkin lymphoma - - - 4 3 7
Carcinoma - 1 1 4 - 6
Neuroblastomaa - 1 3 1 - 5
Rhabdomyosarcoma - I - 3 1 5
Ewing's sarcoma - - 2 2 - 4
Adrenal cortical tumour - 1 2 - 3
Osteosarcoma - 1 1 2
Other 2 3 3 - - 8
Total 20 37 43 50 11 161
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Table III Patterns of double tumour cases
Diagnosis ofsecond tumour
Diagnosis of 1st tumour
Sofi
Osteo- tissue
sarcoma CNS Skin Leukaemia sarcoma Carcinoma
2
21
1
2
2
CNS tumour
Retinoblastoma
Acute leukaemia
Wilms' tumour
Hodgkin's disease
Non Hodgkin lymphoma
Carcinoma
Neuroblastoma
Rhabdomyosarcoma
Ewing's sarcoma
Adrenal cortical tumour
Osteosarcoma
Other
Total
12
5
7
7
3
3
3
1 2 2
35 31 19
5
3
l
2
4
6
4
4
1
l
9
3
I
5b
1 1
1 2
19 18 24
'3 children with Hodgkin's disease; bIncludes 3 patients with carcinoma of the colon.
Table IV Children developing three malignant tumours
Int between
Diagnosis of 1st and 2nd
1st tumour tumour
Int between
Diagnosis 2nd and 3rd
2nd tumour tumour
Choroid plexus
papilloma
Periosteal
fibrosarcoma
of scalp
Extra-osseous
Ewing's tumour
Medulloblastoma
4yr 6m Anaplastic
tumour of
clavicle
7 yr 2 m Osteochondro
-osarcoma
of fibula
16yr 8m Basal cell
carcinoma
22yr 3m Meningioma
6 yr 6 m Osteosarcoma
of pelvis
2yr 10m Sclerosing
osteosarcoma
of ulna
6 m Carcinoma
breast
7yr 9m Basal cell
carcinoma
Patterns oJfassociation between the first and second primary
tumour
The most frequent association of tumours observed, was that
of retinoblastoma followed by osteosarcoma (21 cases), at
intervals of 6-18 years (median 12 years). Five children with
retinoblastoma developed a tumour of the CNS, four a soft
tissue sarcoma, and three patients developed a malignant
melanoma.
An association between acute leukaemia and tumours of
the CNS was observed in twelve patients details of whom are
outlined in Table V. The six children with an initial
diagnosis of acute lymphoblastic leukaemia all had a white
cell count of <20 x 109 1 -1 at presentation and were treated
on protocols for 'standard risk' patients with multiple drug
chemotherapy, cranial irradiation and intrathecal
methotrexate. All six children developed an astrocytic
glioma, albeit of varying histological grading, after intervals
of 4-9 years. One child with acute myeloblastic leukaemia
who received intensive chemotherapy followed by total body
irradiation and an allogeneic bone marrow transplant plus
cyclosporin to prevent graft-versus-host-disease, developed a
meningeal sarcoma 3 years following her initial diagnosis. In
a further five children, an initial tumour of the CNS was
followed by the development of acute leukaemia at intervals
ranging from 18 months to 19 years. All five children had
received radiotherapy for the primary tumour and two
children with medulloblastoma ahd also been treated with
cytotoxic drugs. In both cases, the chemotherapy given
included an alkylating agent.
Another commonly observed combination of tumours was
of double primary CNS tumours (12 cases). In 5 of these the
second tumour was a meningioma and in 4 an astrocytoma.
Three of the latter patients had evidence of Von
Recklinghausen's disease.
Of the 13 patients with a primary Wilms' tumour, 5
subsequently developed a carcinoma between the ages of 20
and 36 and in 3 cases the colon was the site of the second
cancer. There was no evidence of polyposis coli in any of
these patients.
Three children with an adrenal cortical tumour, an
extremely rare form of cancer accounting for only about 1 in
500 of all childhood tumours, have developed a second
tumour (osteosarcoma (1), medulloblastoma (1) and
malignant fibrous histiocytoma (1)). None of these 3 children
had a known family history of malignancy.
Possible aetiological factors
Genetic factors A possible genetic influence was identified
in 7 of the 10 simultaneous cases (Table I) and in 46 of the
remaining 151 patients. The children with recognised genetic
diseases included 33 cases of genetic retinoblastoma (30
children with bilateral disease and 3 unilateral cases with a
positive family history), 12 children with Von
Recklinghausen's disease, 3 with the basal cell naevus or
Gorlin's syndrome, 2 with Turcot's syndrome and one case
each of tuberose sclerosis, Sipple syndrome and Klippel
Trenaunay Weber syndrome. A family history of malignancy
in at least one first degree relative, i.e. parent or sibling, was
3a
2
_I
_I
0
5 10
Lymphoma Other All
3 45
37
16
13
10
7
6
5
5
4
3
2
8
161
Diagnosis
3rd tumour
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Table V Children with acute leukaemia and tumours of the CNS
Interval
FPT SPT (Years) Treatment factors
ALL Astrocytoma 5.0 Chemo+Cranial RT 24Gy
ALL Astrocytoma 3.9 Chemo+Cranial RT 24Gy
ALL Astrocytoma 5.2 Chemo+Cranial RT 24Gy
ALL Astrocytoma 6.0 Chemo+Cranial RT 24Gy
ALL Astrocytoma 9.2 Chemo+C.ranial RT 24Gy
ALL Astrocytoma 7.3 Chemo+Cranial RT 24Gy
AML Meningeal sarcoma 3.5 Chemo+Total body RT 10Gy
Astrocytoma AUL 3.1 Cranial RT 53 Gy
Astrocytoma AML 19.2 Cranial RT 50Gy
Astrocytoma AML 1.5 Cranial RT 50Gy
Medulloblastoma AUL 2.2 Craniospinal RT+ Chemo
Medulloblastoma AML 3.8 Craniospinal RT+Chemo
FPT =First primary tumour; SPT =Second primary tumour; ALL =Acute
lymphoblastic leukaemia; AML=Acute myeloblastic leukaemia; AUL=Acute
undifferentiated leukaemia.
Table VI Genetic factors in non-simultaneous double tumour cases
(excluding genetic retinoblastoma)
Diagnosis ofsecond tumour
Soft
tissue
Genetic factor CNS Skin Leukaemia sarcoma Other All
VRD 3 - 5 1 9
Gorlin's syndrome - 2 - - 2
Sipple syndrome - -
Turcot's syndrome 1
Bilateral Wilms' 1
identified in a further 8 cases with no known genetic disease
(Table VI). Of these, three families had features of the Li
Fraumeni syndrome (Li & Fraumeni, 1969) and three
children had a sibling with cancer, in two of whom the
tumours were concordant (ALL and CNS tumours).
Amongst the 45 children with CNS tumours who
subsequently developed a second cancer, there were 15
children with a known genetic disease (10 with neurofibro-
matosis, 3 with Gorlin's syndrome) and one case each of
Turcot's syndrome and tuberose sclerosis. In addition there
were 4 children who had a first degree relative with cancer
(Table VII).
Treatment factors
The relationship of the second tumour to previous therapy
for the 151 non-simultaneous cases is shown in Table VIII
and discussed in detail below.
Radiotherapy One hundred and twenty five children
received some form of radiation therapy for their first
tumour. In 93 (610%) of these children the second tumour
was considered to be 'radiation associated'; in 52 children
the second tumour was situated within the radiation field, in
25 the tumour developed on the edge of the radiation portals
and in a further 16 children, acute leukaemia developed as
their second tumour.' In the remaining 32 cases the second
tumour developed outside the radiation field and these
second tumours were not considered to be radiation
associated.
Chemotherapy Fifty children, who were all diagnosed since
1962, had received single or multiple agent chemotherapy
either as the sole mode of treatment (5 children) or in
combination with radiotherapy (45 children). The
distribution of second tumours developing in the children
treated with chemotherapy is shown in Table IX.
Osteosarcoma and leukaemia were the most commonly
observed second tumours in patients treated with chemo-
therapy. Thirteen (68%) of 19 children developing leukaemia
as their second tumour had been previously treated with
chemotherapy and in all cases the chemotherapy had
included an alkylating agent. Overall, an alkylating agent
had been used in 38 of the 50 children (Table X). Thirty two
had received cyclophosphamide either as a single agent (10)
or in combination with other drugs (22), whilst six children
had been treated with another alkylating agent, mustine,
lomustine or procarbazine. Twelve children received chemo-
therapy which did not include an alkylating agent and the
second tumours in this group included 5 children with ALL
who developed astrocytomas and 3 children with ALL who
developed Hodgkin's disease.
Hormone therapy A total of 15 patients had received
hormones either as replacement therapy (10 cases); as
contraceptive measures (3 cases) or for menstrual disorders
(2 cases). Two of three patients who had received oestrogen
replacement therapy for endocrine dysfunction subsequently
developed a malignant tumour of the uterus; in one patient
this was a leiomyosarcoma and in the other an adeno-
carcinoma. One child with a pituitary adenoma treated with
growth hormone developed an osteosarcoma of the femur.
Analysis ofaetiologicalfactors by type ofsecond tumour
Osteosarcoma Thirty five children developed an osteo-
sarcoma as a second tumour at intervals ranging from 8
months to 23 years (median 10 years). In 17 children
(48%), the tumour developed within or on the edge of an
irradiated area and of these, 8 had also received chemo-
therapy. Of the 21 children with retinoblastoma who
developed osteosarcoma, 8 of the tumours developed within
the radiation field, 8 in long bones outside the field whilst 5
had not received any irradiation; eight of the children had
also been given cyclophosphamide. Of the 14 osteosarcomas
developing after other primary tumours, 9 were considered
to be radiation associated and of these 5 had also received
chemotherapy. Three of the 14 non-retinoblastoma
associated osteosarcomas occurred in children with a family
history of cancer in at least one first degree relative.
CNS tumours Of the 29 tumours of the CNS occurring as
second primaries, 22 (76%) developed within or on the edge
of the radiation field and were classified as radiation
associated. Nine of these 22 patients had also received
chemotherapy which included cyclophosphamide in four; five
of the children had a genetic disease predisposing to cancer.
Two of the 6 children whose second tumour was not
considered to be radiation associated and who had not
received chemotherapy, had a genetic disease predisposing toSECOND TUMOURS IN CHILDHOOD CANCER PATIENTS 335
Table VII Children with family history of malignancy (excluding those with known
genetic disease)
Diagnosis of Diagnosis of Relative with Type ofcancer
Ist tumour 2nd tumour Interval malignancy cancer
Medulloblastomaa Osteosarcoma 5 yr Mother Ca breast
parietal bone
Medulloblastoma Ca colon 33 yr Father Ca pancreas
PGM Ca breast
Astrocytomaa Ca uterus 25yr Mother Ca breast
Subependymal Lymphoma 3 yr Sister Brain tumour
glioma
Malignant teratoma Sarcoma of liver 8 yr Brother Brain tumour
of ovary
Dysgerminoma Ca colon 14yr Mother Ca brochus
of ovary
ALLab Osteosarcoma 9yr Mother Ca breast
femur Ca uterus
Sister ALL
MGF Ca colon
MU Glioma
MU Chondrosarc
Wilms' tumour Osteosarcoma rib 23 yr Mother Ca cervix
Cousin Wilms' tumour
apossible Li Fraumeni syndrome families; bSibling with concordant tumour;
PGM =Paternal grandmother; MGF =Maternal grandfather; MU =Maternal uncle.
Table VIII Treatment factors possibly predisposing to the development of the second tumour
in the 151 non simultaneous cases
Chemo but No chemo
'RT associated' not 'RT Chemo & 'RT & not 'RT
Diagnosis 2nd tumour but no chemo associated' associated' associated'
Osteosarcoma (35) 9 6 8 12
CNS tumour (29) 13 1 9 6
Carcinoma (22) 9 1 2 10
Leukaemia (19) 6 3 10
Skin tumour (18) 14 - - 4
Soft tissue sarcoma (17) 3 1 5 8
HD/NHL (4) - 2 1 1
Other (7) 2 1 - 4
Total (151) 56 15 35 45
RT associated =Within or on the edge of a radiation field; Chemo chemotherapy.
Table IX Second tumours in patients treated with chemotherapy
Diagnosis ofsecond tumour
Sofi
Osteo- tissue Hodgkin's
1st tumour sarcoma CNS Leukaemia sarcoma Carcinoma disease Other All
Leukaemia 1 7 3 - 1 3 15
Lymphoma 2 2 6 2 - - 12
Retinoblastoma 8 1 - 1 - - 10
Wilms' tumour 1 - - 3 2 - 6
CNS 1 2 - - - 3
Other 1 - 2 - - - 1 4
Total 14 10 13 6 3 3 1 50
( )a (40) (30) (68) (33) (13) (100)
aFigures in brackets represent percentage treated with chemotherapy within that diagnostic
group.336 J.E. KINGSTON et al.
Table X Chemotherapy given to children developing second
tumours
No developing
leukaemia
No of as 2nd
Drug(s) used cases tumour
Cyclophosphamide as single agent 10
Multiple drugs+cyclophosphamide 22 9
Multiple drugs+other alkylating agent 6 4
Multiple drugs - no alkylating agent 10
Single agent - non alkylating 2
50 13
neoplasia (one with neurofibromatosis and the other with
polyposis coli).
Carcinoma Of the 22 cases of carcinoma developing as a
second tumour, 13 were considered to be radiation
associated, 5 developed outside radiation portals and 4 had
not been irradiated. There were 6 cases of colorectal cancer,
5 of which were radiation associated, and 4 cases of thyroid
carcinoma, 3 of which were thought to be related to previous
radiotherapy. A difference in the latent intervals to diagnosis
of carcinoma was noted between the radiation associated
carcinomas, (median interval 14 years) and the remainder
(median interval 26 years). There were no obvious
dissimilarities between the two groups with regard to factors
such as genetic disease, chemotherapy or the spectrum of
primary tumour type, to account for the observed difference
in the latent interval.
Leukaemia Leukaemia developed as a second tumour in 19
patients, at a median interval of 5 years following treatment
for the first tumour. Sixteen patients developed a leukaemia
classified as either AML or an undifferentiated leukaemia
and 3 developed acute lymphoblastic leukaemia. Ten of the
children had been treated with both chemotherapy and
irradiation, 6 by irradiation alone and 3 with chemotherapy
alone (Table XI).
Table XI Treatment given to children subsequently developing
leukaemia as a second tumour
Diagnosis
Ist tumour RTalone Chemo alone RT+chemo Total
CNS tumour 3 - 2 5
Lymphoma
(HD/NHL) _ 2 4 6
Acute leukaemia - 3 3
Retinoblastoma 1 - I
Osteosarcoma 1 I
Ewings sarcoma - 1 I
Wilms' tumour I -
Neuroblastoma - 1 - I
Total 6 3 10 19
Skin Eighteen patients developed a second primary of skin
either basal cell carcinoma (14) or malignant melanoma (4);
14 (78%) were considered to be radiation associated. None
had received chemotherapy. Three of the 4 patients with
malignant melanoma had previously been treated for retino-
blastoma and two of the patients with basal cell carcinoma
had the basal cell naevus syndrome.
Soft tissue sarcomas Five soft tissue sarcomas developed
after treatment for a tumour of the CNS, none were
radiation associated and none of the patients had received
chemotherapy; four occurred in patients with neurofibro-
matosis. Four soft tissue sarcomas developed after treatment
for Wilms' tumour and all were considered to be 'radiation
associated'. In addition, three of the four children had been
treated with actinomycin-D.
Discussion
It is evident that the number of children developing second
primary tumours is increasing. As many multiple primary
tumour cases have already been identified for the decade
1970-79 as for the previous decade, although the period at
risk for patients diagnosed during this later period is shorter.
This increase may be explained partly by the increased
numbers of survivors at risk, although it is likely that
treatment factors have contributed to induction of the
second malignancy in a significant number of patients.
Estimates of the risk of developing a second histologically
distinct malignancy following childhood cancer vary
substantially. In an analysis of the LESG data by Mike et al.
(1982), the estimated cumulative risk was 3.3% at 20 years
whilst in a study by Li (1977), the cumulative risk was 12%
for 5-24 years from diagnosis. For survivors of Ewing's
sarcoma, Strong et al. (1979) suggested that the cumulative
risk of radiation related second tumours might be as high as
35% at 10 years. However since the standard error was 15%,
these figures are subject to considerable uncertainty. In a
study carried out by the CCRG (Hawkins et al., 1987),
about 4% of 3 year survivors of childhood cancer had
developed a second primary cancer during the subsequent 20
year period.
The patterns of second tumours appear to be changing;
before 1970 the two tumour types most frequently associated
with the development of a second tumour were genetic
retinoblastoma and tumours of the CNS, whereas since 1970,
children with leukaemia and lymphoma have been the major
group developing second tumours. This may reflect the
improvement in survival for children with leukaemia and
lymphoma following the introduction of intensive combined
modality treatment programmes and also the longer latent
interval for the types of second malignancies most commonly
seen in children treated for solid tumours.
The association of acute leukaemia with tumours of the
central nervous system (12 patients in this series) has also
been noted by Meadows et al. (1977) who observed five
patients with leukaemia or lymphoma and glioma in an
analysis of 102 second malignant neoplasms observed by
members of the Late Effects Study Group. Meadows and her
colleagues suggested that the association might be part of a
new genetic cancer syndrome. Support for this hypothesis
comes from a study of 643 children with CNS tumours
carried out by Farwell and Flannery, (1984a) who found an
excess of haemopoietic-lymphatic cancer in the siblings of
the children with tumours of the CNS.
In our series, osteosarcoma and tumours of the CNS were
the most frequently observed second malignant neoplasms.
Twenty one of the osteosarcomas occurred in children with
retinoblastoma. Our findings are similar to those of the Late
Effects Study Group (Meadows et al., 1985), who have also
observed a high frequency of osteosarcoma occurring as a
second malignancy in their childhood cancer patients. In our
series of 45 children with primary tumours of the CNS, 12
(27%) of the second tumours were also in the CNS. Five of
the 12 had evidence of Von Recklinghausen's disease. In the
LESG series, (Meadows et al., 1985) there were 31 children
who had their first primary in the CNS but of these only 4
(13%) developed a second tumour within the CNS. In a
review of 670 children with CNS tumours, Farwell and
Flannery (1984b) found three children who had developed a
second tumour within the CNS; the expected number was
0.16 giving a relative risk of 19.
The main points of difference between the findings of the
LESG and those of our study are, firstly, the relative
infrequency of children with neuroblastoma developing a
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larger number of children with CNS tumours and acute
leukaemia in our study who have developed second tumours.
This may reflect selection in referral patterns within the
various institutions of the LESG although it is possible that
different therapeutic approaches may have contributed to the
differences observed. Also the early LESG reports included
only patients diagnosed before 1970, when few cases of
leukaemia survived.
In this series, a total of 16 children with acute leukaemia,
14 with ALL and two children with AML, developed second
tumours, a larger number than has been reported in any
other single series. Thirteen developed a solid tumour (CNS
(7), Hodgkin's disease (3), osteosarcoma (1), neuroblastoma
(1) and carcinoma of parotid gland (1)) and three a new
leukaemia. Askold et al. (1981) reviewed the literature and
found reports of 33 children with ALL who had developed a
second malignancy. Nine of these had developed a solid
tumour and 13 a second leukaemia. Seven of the cases had
developed histiocytic medullary reticulosis (HMR) as the
second malignancy at intervals of 3-8 months following the
diagnosis of ALL. Although we know of two such cases in
Britain we have not included them in our series because of
the doubt about the pathogenesis of HMR. There have been
reports suggesting that HMR is a reaction to a viral
infection in an immunocompromised host (Risdall et al.,
1979).
In this series of 151 patients with non-simultaneous
tumours, 77 of the 125 children treated with radiation
developed their second tumour within or on the edge of the
radiation field whilst a further 16 children developed acute
leukaemia making a total of 93 (61%) which could be
described as 'radiation associated'. Twenty one of these
radiation related tumours occurred in children who also had
a genetically determined susceptibility. In a report by Li and
colleagues (1977), fifteen of 410 patients surviving for 5 years
or more developed a second malignant tumour and all but
one of the fifteen second cancers described arose in tissues
previously irradiated. In an analysis of the LESG data
(Meadows et al., 1985), 208 (67%) of 308 second or
subsequent tumours were classified as radiation associated.
The carcinogenic potential of low doses of radiation in the
development of tumours such as thyroid, salivary gland and
brain tumours has also been stressed (Modan et al., 1974;
Curtin et al., 1977). Twenty five of the second tumours
associated with radiation therapy in this series developed on
the edge of a radiation field.
The association between retinoblastoma and osteo-
sarcomas occurring either within or outside the radiation
field is well recognised (Reese et al., 1949; Abramson et al.,
1976). In addition, there appears to be a specific association
between retinoblastoma and other types of sarcoma and
possibly also with melanoma (DerKinderen et al., 1986). In
this series there were 21 cases of osteosarcoma following
treatment for retinoblastoma. Equal numbers of the osteo-
sarcomas developed in long bones outside the radiation field
as developed within the radiation field, and a further five
had not received any radiation. This suggests that genetic
predisposition is probably the underlying factor in the
development of second tumours in patients with retino-
blastoma; whilst the development of osteosarcomas in bones
of the orbit, an extremely rare site for primary osteo-
sarcoma, suggests that patients with genetic retinoblastoma
may demonstrate a radiation sensitivity. The evidence for
these conclusions and a more detailed analysis of the second
primary tumours occurring in our series of children with
retinoblastoma are presented elsewhere (Draper et al., 1986).
Fifty children in our series had received cytotoxic drugs. A
number of chemotherapeutic agents have been implicated in
the development of second malignancies (Schmahl et al.,
1982) and the drugs most frequently reported have been the
alkylating agents including busulphan, chlorambucil,
melphalan and cyclophosphamide. Thirty eight children in
this series had received an alkylating agent and in 32 this
was cyclophosphamide.
Since the introduction of intensive chemotherapy during
the early 1970s, the second malignancy most frequently
observed in association with cytotoxic therapy has been
acute nonlymphocytic leukaemia (ANLL). In this series, 13
of the 38 second neoplasms that developed after treatment
with an alkylating agent were acute leukaemias. In an
analysis of the LESG data (Meadows et al., 1985), 49 of 292
children developing second tumours had been treated with
chemotherapy alone and all but two had been treated with at
least one alkylating agent. Twelve of the 49 cases were
secondary leukaemias. A significantly increased risk of
secondary leukaemia has been shown in a separate analysis
of two year survivors of childhood cancer treated in
institutions of the LESG (Tucker et al., 1984). The relative
risk of secondary leukaemia was strongly associated with the
dose of alkylating agent. Several authors have suggested that
the risk of developing a second malignant neoplasm is
greatest in patients receiving both chemotherapy and radio-
therapy, and there is considerable evidence for this from
studies of adult patients (Cadman et al., 1971; Arseneau et
al., 1977). Forty five children (30%), in this series had
received both chemotherapy and radiotherapy although in
only 35 of these was the radiotherapy thought to have been
contributory to the induction of the second tumour.
The occurrence of tumours of the uterus in two patients
following oestrogen replacement therapy is of particular
interest in view of the occurrence of endometrial cancer
following the use of oestrogens in post menopausal women
(Jick et al., 1980). The development of an osteosarcoma in a
child with a pituitary adenoma treated with growth hormone
is also noteworthy. Meadows and colleagues, (1980),
reported that the development of bone sarcoma occurring as
a second neoplasm was significantly influenced by prior
radiation therapy and genetic predisposition. In a subsequent
analysis of the LESG data, Tucker and colleagues (1985),
showed that exposure to alkylating agents was associated
with a significant 2-fold risk of bone cancer and that this
was independent of radiation therapy. There is a high
incidence of osteosarcoma during adolescence with the peak
occurring earlier in girls than in boys, possibly related to the
earlier growth spurt in girls. As the normal growth spurt is
under hormonal control it is interesting to speculate that an
abnormal hormonal influence might also be a factor in the
development of secondary osteosarcoma.
It is well recognised that genetic factors can influence the
development of a malignancy and in addition to the genetic
form of retinoblastoma, several inherited conditions such as
the basal cell naevus syndrome, Von Recklinghausen's
disease and tuberose sclerosis are known to be associated
with the development of childhood cancer and of multiple
primary neoplasms (Mulvihill 1977). Meadows et al. (1985)
found the influence of genetic or familial factors in 82 of 292
(28%), of their patients and 73 (25%) had a genetic disease
known to predispose. to cancer, a much higher incidence
than in the overall population of children who develop
cancer. A recognised genetic disease was present in 53 (33%)
of our total series of 161 cases and there was a family
history of malignancy in at least one first degree relative in a
further 8 cases.
Cancers that have a genetic basis often occur as multiple
tumours which are relatively tissue specific, for example
osteosarcoma with bilateral retinoblastoma. The retino-
blastoma gene has been mapped to band 14 on the long
arm of chromosome 13 and mutations at this locus result in
the development of retinoblastoma. Of considerable interest
is some recent research work which has demonstrated
that osteosarcoma may result from a similar mutation at
the q14 band of chromosome 13 (Dryja et al., 1986). Obser-
vation of the patterns of double tumours may help direct
paths of research in molecular biology and thereby increase
our understanding of the molecular mechanisms predisposing
to the development of multiple primary tumours.
In conclusion, the number of second primary tumours can
be expected to increase as a consequence of the growing338 J.E. KINGSTON et al.
numbers of long term survivors of childhood cancer and as
the trend for more intensive chemotherapy and combined
modality treatments becomes more widely accepted. We
predict that this increase will be most pronounced in those
childhood cancer survivors with a genetic susceptibility.
Therefore it behoves clinicians to identify children with
cancer prone conditions so that treatment protocols
containing potentially oncogenic therapies such as alkylating
agents and irradiation may be reconsidered for such patients.
With the introduction of new, effective, non-alkylating
cytotoxic agents, it may be possible to eliminate alkylating
agents from protocols for patients with a favourable
prognosis, thereby reducing the risk of inducing a second
tumour without compromising survival. Long term follow up
of childhood cancer patients is needed to determine the
magnitude of the problem of second primary malignancies
and to continue identification of possible aetiological factors.
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